ArticleThe EMBO journal2009
Long-term potentiation: two pathways meet at neurogranin.
Article in The EMBO journal, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer's disease and mild cognitive impairment.Translational psychiatry · 2020Pooled it
- Effects of the neurogranin variant rs12807809 on thalamocortical morphology in schizophrenia.PloS one · 2013Trial
- Phytohemagglutinin: A Tool for Inducing Neuroinflammation Mediated In Vitro and In Vivo Modeling of Alzheimer's Disease Pathology.Cell biochemistry and function · 2026Article
- Monitoring synaptic pathology in Alzheimer's disease through fluid and PET imaging biomarkers: a comprehensive review and future perspectives.Molecular psychiatry · 2024Review
- Alzheimer's Disease beyond Calcium Dysregulation: The Complex Interplay between Calmodulin, Calmodulin-Binding Proteins and Amyloid Beta from Disease Onset through Progression.Current issues in molecular biology · 2023Review
- Evaluation of Synaptic and Axonal Dysfunction Biomarkers in Alzheimer's Disease and Mild Cognitive Impairment Based on CSF and Bioinformatic Analysis.International journal of molecular sciences · 2022Article
- Neurogranin as a Reliable Biomarker for Synaptic Dysfunction in Alzheimer's Disease.Diagnostics (Basel, Switzerland) · 2021Article
- Neurogranin and Neuronal Pentraxin Receptor as Synaptic Dysfunction Biomarkers in Alzheimer's Disease.Journal of clinical medicine · 2021Article
- Association of Clusterin Levels in Cerebrospinal Fluid with Synaptic Degeneration Across the Alzheimer's Disease Continuum.Neuropsychiatric disease and treatment · 2020Article
- Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer's disease pathogenesis.Cellular and molecular life sciences : CMLS · 2019Review
- The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer's disease.Acta neuropathologica · 2019Article
- Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers.Neurology · 2017Article
- Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.Brain : a journal of neurology · 2015Article
- Impact of the genome wide supported NRGN gene on anterior cingulate morphology in schizophrenia.PloS one · 2012Article
- Neurogranin phosphorylation fine-tunes long-term potentiation.The European journal of neuroscience · 2011Article
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.